CRISPR Therapeutics AG Stock Prediction
AI-powered sentiment analysis and prediction trends for CRSP, updated each market day.
CRSP AI Sentiment
AI sees no strong directional signal for CRISPR Therapeutics AG stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Sector
Exchange
Market Cap
$4,964,360,336
Cap Tier
Employees
393
Headquarters
ZUG
Listed Since
Oct. 19, 2016
Website
CRSP Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CRSP Volatility
CRISPR Therapeutics AG has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
